{"id":47815,"date":"2026-03-25T03:13:06","date_gmt":"2026-03-25T03:13:06","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/47815\/"},"modified":"2026-03-25T03:13:06","modified_gmt":"2026-03-25T03:13:06","slug":"novo-nordisk-expands-obesity-portfolio-with-oral-drug-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/47815\/","title":{"rendered":"Novo Nordisk Expands Obesity Portfolio with Oral Drug Trial"},"content":{"rendered":"


\n\t
\n\t\tNovo<\/a>, Nordisk<\/a>\t\t
\n\t\t25.03.2026 – 03:57:51 | boerse-global.de
\n\t <\/p>\n

Novo Nordisk expands its weight-loss strategy with a new oral drug trial, paying Lexicon $10M. The firm also buys back DKK 2.1B in shares amid a 28.5% stock decline this year.<\/p>\n


\n
\n\t
\n <\/p>\n

\t\t\t\t\t\t\t\t\t\t\t <\/p>\n

\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t \"Novo <\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t Novo Nordisk Expands Obesity Portfolio with Oral Drug Trial – Foto: \u00fcber boerse-global.de\t\t\t\t\t <\/p>\n

\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t<\/a><\/p>\n

\t\t\t\t
\n
\n
\n
\n
\n\t
\n
\n\t
\n
\n\t
\n
\n\t
\n\t <\/p>\n

The Danish pharmaceutical giant is broadening its strategy in the lucrative weight-loss market beyond its established injectable treatments. A new Phase 1 clinical study for an oral medication candidate has commenced, marking a significant strategic shift and triggering an initial payment to a key partner.<\/p>\n

Strategic Diversification Amid Market Pressure<\/p>\n

Facing intensifying competition in the anti-obesity sector, Novo Nordisk is actively diversifying its development pipeline. The company’s reliance on blockbuster drugs like Wegovy is being supplemented by new approaches. The recent initiation of a Phase 1 trial for an oral, non-incretin-based therapy represents a calculated move to secure long-term market share. The first conclusive data from this early-stage study is not expected before early 2027.<\/p>\n

The candidate at the center of this development is LX9851, a pill designed to treat obesity and related metabolic conditions. The weekend-launched trial will initially assess safety and dosage in 96 overweight participants. For Lexicon Pharmaceuticals, the licensing partner, the study’s start activated an immediate $10 million milestone payment. Should the drug successfully navigate all future clinical and regulatory phases, Lexicon stands to receive up to $1 billion in additional milestone payments, plus future royalties on sales.<\/p>\n

Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n

Share Buybacks Provide Structural Support<\/p>\n

Alongside its research initiatives, Novo Nordisk’s management continues to execute its capital return program. As part of this ongoing effort, the company repurchased approximately 7.85 million B-shares for nearly DKK 2.1 billion by March 20, 2026. The broader buyback program, launched in February, is authorized to allocate up to DKK 15 billion over a twelve-month period. These transactions have resulted in the company holding 0.6% of its share capital as treasury stock.<\/p>\n

This aggressive repurchase activity serves as a key mechanism to support the firm’s capital structure, especially during a period of notable stock price weakness. The equity has recently traded just above its 52-week low, closing at \u20ac31.95 in the latest session. Since the start of the year, the share price has declined by 28.50%.<\/p>\n

Ad<\/p>\n

Novo Nordisk Stock: New Analysis – 25 March<\/p>\n

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n

Read our updated Novo Nordisk analysis…<\/a><\/p>\n

\t
\n
\n
\n\t <\/p>\n

\t\tTrading lernen. Jetzt Platz sichern
\n\t\t\t\t\t\"<b>Trading<\/p>\n

\t\t\tDie trading-house B\u00f6rsenakademie bringt dich in exklusiven Live-Webinaren n\u00e4her an erfolgreiche Trading-Entscheidungen. 100% kostenlos. 100% Expertenwissen. Erhalte klare Marktanalysen, konkrete Setups und direkt anwendbare Strategien von erfahrenen Profis. Jetzt kostenlos anmelden und live dabei sein.
Lernen. Traden. Verdienen. <\/a> <\/a><\/p>\n

\t
\n\t <\/p>\n


\n\t
\n\t\t\t\t\t\t\tDK0062498333 | NOVO | boerse | 68979883 | \t\t\t\t \n\t<\/p>\n


\n <\/p>\n","protected":false},"excerpt":{"rendered":" Novo, Nordisk 25.03.2026 – 03:57:51 | boerse-global.de Novo Nordisk expands its weight-loss strategy with…\n","protected":false},"author":2,"featured_media":47816,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[949,15386,26863,5691,3845,272,357,13590,19810,1967,3571],"class_list":["post-47815","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-drug","tag-expands","tag-lexicon","tag-nordisk","tag-novo","tag-novo-nordisk","tag-obesity","tag-oral","tag-portfolio","tag-the","tag-trial"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116287635702075695","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/47815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=47815"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/47815\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/47816"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=47815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=47815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=47815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}